Why the study?
To explore the mechanistic role and antihypertensive effects of finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, in hypertension management.
Does finerenone improve blood pressure regulation and cardiorenal protection in hypertension compared to traditional mineralocorticoid receptor antagonists?
Does finerenone improve blood pressure regulation and cardiorenal protection in hypertension compared to traditional mineralocorticoid receptor antagonists?
Finerenone is a promising therapeutic candidate for hypertension management, offering dual benefits of blood pressure reduction and cardiorenal protection with a favorable safety profile.
Answers are grounded in this paper and cite their sources.
Supports consideration of finerenone in hypertension; leaves open confirmation by head-to-head RCTs.
This review explores the mechanistic role of finerenone, a selective nonsteroidal mineralocorticoid receptor (MR) antagonist, in the management of hypertension. Finerenone exerts its antihypertensive effects by selectively targeting MR pathways, thereby modulating blood pressure and offering substantial cardiorenal protection. By inhibiting aldosterone activity within the renin–angiotensin–aldosterone system, it reduces sodium and water retention, oxidative stress, fibrosis, and inflammation in renal and cardiovascular tissues. This narrative review is based on a comprehensive analysis of peer-reviewed preclinical and clinical studies retrieved from databases such as PubMed and Scopus, using terms including “finerenone,” “hypertension,” “mineralocorticoid receptor antagonists,” and “cardiorenal protection.” The review highlights finerenone’s superior efficacy and safety profile compared to traditional MR antagonists such as spironolactone. These findings underscore its potential to reduce blood pressure and prevent hypertension-induced organ damage with fewer adverse effects. The dual action of finerenone in blood pressure regulation and organ protection positions it as a promising therapeutic candidate. Ongoing research is warranted to further optimize its clinical applications in hypertension and related complications.
No takes yet. Share an insight, caveat, or question.
Prasad et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: